Johnson & Johnson, Pulmonary Hypertension

Startseite
Schweiz
Allschwil
Johnson & Johnson, Pulmonary Hypertension

On Facebook we share a more personal view of us and our company culture. Community guidelines https://www.jnj.com/social-media-community-guidelines

At Johnson & Johnson, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need. Please read our community guidelines on https://www.jnj.com/social-media-community-guidelines or visit our website https://www.janssen.com/

21/11/2025

: can affect adults and children of all ages, but its impact is not the same for everyone. Women are more than three times as likely as men to develop (PAH), and people of color often face poorer health outcomes.

In recognition of , hear from Gerry as she shares her experience living with PAH and the importance of having support.

19/11/2025

This November, we join the (PH) community in celebrating and supporting the Pulmonary Hypertension Association's (PHA) theme, “EmPHasize Your Health.” From raising awareness to advocating for better care, we can make a lasting impact for those living with PH.

Visit the PHA’s site to get involved: https://phassociation.org/get-involved/raise-awareness/awareness-month/?sf229931610=1

10/11/2025

In recognition of , the Johnson & Johnson World Headquarters tower shined purple in solidarity with the (PH) and community. Increasing awareness of PH is vital to improving care for those living with this progressive disease.

Learn more here: https://phassociation.org/wp-content/uploads/2025/10/PH_Awareness_PHFactSheet-2025.pdf?sf229585092=1

07/11/2025

: (PAH) is a serious lung condition that can cause high blood pressure in the lungs and lead to right heart failure. It can develop alongside heart or lung disease, blood clots or genetics, and sometimes the cause is unknown.

As a proud sponsor of the Pulmonary Hypertension Association, we encourage you to learn more by visiting: https://bit.ly/480MeGu

04/11/2025

November is , a time to recognize the (PH) and community and join efforts to raise awareness, advocate for better care and support those living with PH.

Learn more from the Pulmonary Hypertension Association and see how to get involved: https://bit.ly/3WDeTuY

21/10/2025

For more than 25 years, we’ve helped transform the treatment landscape for (PAH). From pioneering the first oral and fixed-dose combination therapies to building a portfolio that addresses three foundational PAH pathways, our work has been driven by one goal: improving outcomes and helping patients live better lives every day.

17/10/2025

: (PH) most often affects people between the ages of 30 and 60. It often takes patients years to receive a proper diagnosis, which can delay care and worsen outcomes. As we age, the risk of developing Group 1 PH, known as (PAH), increases.

25/09/2025

Today is . We’re proud to join the global effort in highlighting the importance of lung health.

Our mission is rooted in advancing scientific innovation and improving the lives of those affected by serious lung conditions like lung cancer and (PAH). Together, we stand in support of patients and the worldwide lung health community.

19/09/2025

: Approximately 43,000 new cases of (PAH) are diagnosed globally each year.

We hope to raise awareness and provide support to help those who are living with manage the condition.

Find patient resources and more by visiting our PH site: https://bit.ly/4nE9wai

20/08/2025

We’re passionate about supporting those with (PH), which is why we never lose sight of the people behind the disease.

Every step we take, whether it’s advancing research, expanding access to care or raising awareness, is rooted in our commitment to making a real difference in the lives of patients and their families.

Explore our PH site to learn more about our efforts: https://www.emea.jnjwithme.com/en/pulmonary-arterial-hypertension?sf227712133=1

08/08/2025

: About 1,000 new cases of (PAH) are diagnosed every year in the United States.

At Johnson & Johnson, we work to improve outcomes and transform PAH into a long-term, manageable condition so that patients can live longer, healthier lives.

23/07/2025

As a leader in (PAH), we are dedicated to making a meaningful impact on patients’ lives by offering a comprehensive portfolio of treatments that address all three foundational guideline-recommended pathways for this progressive disease.

Adresse

Hegenheimermattstrasse 95
Allschwil
4123

Telefon

+41615656565

Webseite

https://www.janssen.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Johnson & Johnson, Pulmonary Hypertension erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.